Drug · DIN 02432803
EXELON PATCH 15
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 26, 2022; first marketed April 17, 2015.
- Drug Identification Number (DIN)
- 02432803
- Company (DIN owner)
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Patch
- Route
- Transdermal
- Therapeutic class (ATC)
- Rivastigmine N06DA03
- Class
- Human
- Record last updated
- July 30, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RIVASTIGMINE | 13.3 MG | 24 HOUR |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 3, 2022: NOC 29131New Drug Submission (NDS) · Administrative: Change in Product Ownership
- October 20, 2014: NOC 16202Supplement to a New Drug Submission (SNDS) · New strength for moderately severe alzheimer's dementia. revised indication for approved strengths to include patients with moderately severe alzheimer's dementia